Advances in Fmoc solid‐phase peptide synthesis

Abstract

Today, Fmoc SPPS is the method of choice for peptide synthesis. Very‐high‐quality Fmoc building blocks are available at low cost because of the economies of scale arising from current multiton production of therapeutic peptides by Fmoc SPPS. Many modified derivatives are commercially available as Fmoc building blocks, making synthetic access to a broad range of peptide derivatives straightforward. The number of synthetic peptides entering clinical trials has grown continuously over the last decade, and recent advances in the Fmoc SPPS technology are a response to the growing demand from medicinal chemistry and pharmacology. Improvements are being continually reported for peptide quality, synthesis time and novel synthetic targets. Topical peptide research has contributed to a continuous improvement and expansion of Fmoc SPPS applications. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.

Cited by papers we hold 6

• Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines · 2025
  No notice
• Therapeutic peptides: current applications and future directions · 2022
  No notice
• Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region · 2021
  Not checked
• Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues · 2021
  No notice
• Antifungal Peptides as Therapeutic Agents · 2020
  No notice
• Recent Progress in the Chemical Synthesis of Class II and S-Glycosylated Bacteriocins · 2018
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.